Monitor Windward Bio's upcoming clinical data readouts for WIN378 (POLARIS-1 Phase 2/3 in asthma, SIRIUS Phase 2 in COPD) as key catalysts. Qiming's continued participation in the IPO signals long-term commitment.
Price Chart
How similar events traded
Executive Summary
Qiming Venture Partners' portfolio company Windward Bio (WWB) listed on Nasdaq at $17.00 per share, closing at $28.50 on its first day for a market cap of approximately $1.69 billion. Qiming participated in the IPO financing round and had previously invested in Windward Bio's Series A and Series B rounds.
Key Facts
- Windward Bio (WWB) priced its IPO at $17.00 per share
- Shares closed at $28.50 on first trading day, up 68% from IPO price
- Market capitalization approximately $1.69 billion
- Qiming Venture Partners participated in IPO financing round
- Windward Bio's lead program WIN378 is in Phase 2/3 for severe asthma and Phase 2 for COPD
- Windward Bio holds exclusive global rights (excluding Greater China and certain Asian countries) to WIN378 via licensing from Kelun-Biotech and Harbour BioMed
- Windward Bio licensed WIN027 from Qyuns Therapeutics
Financial Impact
IPO raised undisclosed amount at $17.00 per share; first-day close at $28.50 implies a market cap of ~$1.69 billion
Risk Factors
- Windward Bio is a clinical-stage company with no approved products
- WIN378 and WIN027 are in early-to-mid-stage clinical trials; regulatory and commercial risks remain
- Licensing agreements with Kelun-Biotech, Harbour BioMed, and Qyuns Therapeutics introduce counterparty and territorial restrictions
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-prn-302939481 |
Track record
15 reports on WWB
Filters
- Nov 16, 2026today Press Release Neutral 5/10 Entry $30.04 Now $30.04 +0.00% settles Dec 16
- Nov 13, 20263d ago Press Release Bullish 5/10 Viewing Entry $18.35 Now $30.04 +63.71% settles Dec 15
- Nov 13, 20263d ago EFFECT Neutral 6/10 Entry $28.50 Now $30.04 +5.40% settles Dec 14
- Nov 12, 20264d ago 3 Neutral 2/10 Entry $28.50 Now $30.04 +5.40% settles Dec 14
- Nov 12, 20264d ago 3 Neutral 1/10 Entry $28.50 Now $30.04 +5.40% settles Dec 14
- Nov 12, 20264d ago 3 Neutral 2/10 Entry $28.50 Now $30.04 +5.40% settles Dec 14
- Nov 12, 20264d ago Press Release Neutral 5/10 Entry $28.50 Now $30.04 +5.40% settles Dec 14
- Nov 12, 20264d ago 3 Neutral 3/10 Entry $28.50 Now $30.04 +5.40% settles Dec 14
- Nov 12, 20264d ago 3 Neutral 2/10 Entry $28.50 Now $30.04 +5.40% settles Dec 14
- Nov 12, 20264d ago 3 Neutral 2/10 Entry $28.50 Now $30.04 +5.40% settles Dec 14
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers